MedTrace Logo

Rivaroxaban Anticoagulation for Superficial Vein Thrombosis

NCT02123524 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 85

Last updated 2018-12-04

No results posted yet for this study

Summary

This is a Phase III, randomized, placebo controlled, blinded, parallel two arm, multicentre trial that will compare rivaroxaban 10mg daily with placebo in patients with symptomatic leg Superficial Vein Thrombosis (\> or = 5cm) that otherwise would not initially be treated with anticoagulant therapy.

Conditions

  • Symptomatic Superficial Vein Thrombosis

Interventions

DRUG

Rivaroxaban

DRUG

Placebo

Sponsors & Collaborators

Principal Investigators

  • Clive Kearon, MD · McMaster University/ Hamilton Health Sciences, Juravinski Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-11
Primary Completion
2018-12-03
Completion
2018-12-03

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02123524 on ClinicalTrials.gov